Hematologic Cancers News

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.

Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study

Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study

Although results indicated rivaroxaban decreased the risk of VTE and VTE-related death in patients with cancer, the benefit was not maintained at study conclusion.

Changes in Microbial Diversity in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Changes in Microbial Diversity in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Loss of intestinal bacterial diversity in patients undergoing AHCT may be comparable to reductions experienced by patients undergoing alloHCT.

CAR-T Cells Successfully Manufactured at Point-of-Care

CAR-T Cells Successfully Manufactured at Point-of-Care

CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.

CHIP Associated with Poorer Outcomes in Lymphoma

CHIP Associated with Poorer Outcomes in Lymphoma

Clonal hematopoiesis of indeterminate potential is associated with shorter overall and event-free survival after autologous transplant in lymphoma.

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

BCMA expression did not correlate with clinical response.

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

Patients saw a deepening of responses over time.

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure

Drug Sensitivity Is Genotype-Dependent: Study

Drug Sensitivity Is Genotype-Dependent: Study

Genetically defined mouse models of AEL could help researchers find novel treatment approaches.

New Standard of Care in CLL Proposed for Older Patients

New Standard of Care in CLL Proposed for Older Patients

Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo

CAR-T and Ibrutinib: Better Together?

CAR-T and Ibrutinib: Better Together?

Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.

Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia

Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia

Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.

Bendamustine-Rituximab-Bortezomib Promising in R/R Waldenström Macroglobulinemia

Bendamustine-Rituximab-Bortezomib Promising in R/R Waldenström Macroglobulinemia

High rates of PFS found with salvage treatment with BRB regimen in patients with R/R Waldenstrom macroglobulinemia.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs